ZW 09-11 GMP Lab for production of PET tracers for clinical and translational research Luc Mortelmans, Guy Bormans, Koen Van Laere, Christophe Deroose,

Slides:



Advertisements
Similar presentations
PET                                          .
Advertisements

Organizational Structure of a Hospital
Lesson 16 Nuclear Medicine. What is Nuclear Medicine? Diagnosis and Treatment of Disease using small amounts of radio-nuclides (radiopharmaceuticals)
King Abdul-Aziz University Diagnostic Radiology Department MS.Nouf Al-Zahrani DR. Saddiq Jastniah Introduction to Nuclear Medicine 2 nd year.
PET Radiopharmaceuticals by Stephen M. Karesh, Ph.D.
16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.
RADIOPHARMACEUTICAL R & D
Topics in Medical Physics Xiaoming Zheng, PhD. School of Dentistry and Health Sciences December 2009, Chengdu.
Small animal PET as non-invasive tool for preclinical imaging Marta Oteo Vives Biomedical Applications of Radioisotopes and Pharmacokinetic.
PHYSICS IN NUCLEAR MEDICINE: QUANTITAITVE SPECT AND CLINICAL APPLICATIONS Kathy Willowson Department of Nuclear Medicine, Royal North Shore Hospital University.
Single Photon Computerized Tomography SPECT neuroimaging Seyed Kazem Malakouti, MD Faculty of Iran University of Medical Sciences Seyed Kazem Malakouti,
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Radioisotopes in Medicine
An Introduction to Molecular Imaging in Radiation Oncology : A report by the AAPM Working Group on Molecular Imaging in Radiation Oncology(WGMIR) Tuesday.
Dr P Shanmuga Sundaram, MBBS, DRM, DNB (N Med), MNAMS
Nuclear Medicine By: Amanda Taulanga 3B.
PET POSITIVE EMISSION TOMOGRAPHY. WHAT IS IT? Small amounts of radionuclides (radioactive material) are injected into the body The radionuclides produce.
PET/CT & PET/MRI Radiopharmacy
Introduction to Nuclear Medicine
There are currently 26 million people worldwide with Alzheimer’s disease. This figure is projected to grow to more than 106 million people by 2050.
PET Tracers Developments
An Overview of Molecular Imaging by Dr Lohith T G MMST 2 nd year Indian Institute of Technology Kharagpur.
M EDICAL I MAGING Packet #5 Chapter #22. I NTRODUCTION Medical imaging provides visual representations of body parts, tissues, or organs, for use in clinical.
MicroPET: Radiotracer Imaging of Rodents and Non-Human Primates Alexander K. Converse, PhD University of Wisconsin–Madison Waisman Center - Brain Imaging.
Organizational Structure of a Hospital
Nuclear Medicine. The History Henri Becquerel 1896-Discovered mysterious “rays” Nobel Prize Marie Curie named mysterious rays “radioactivity”
By Nazli Gharraee April 2008
00 K. Van Liempt Faculty of Medicine The University of Antwerp Faculty of Medicine University Hospital Antwerp.
Positron Emission Tomography (PET)
ZW GMP Lab for production of PET tracers for clinical and translational research Luc Mortelmans, Guy Bormans, Koen Van Laere, Christophe Deroose,
PET-CT in Scotland Dr Fergus McKiddie John Mallard PET Centre Aberdeen Royal Infirmary.
Design and simulation of micro-SPECT: A small animal imaging system Freek Beekman and Brendan Vastenhouw Section tomographic reconstruction and instrumentation.
Procedure Guidelines and Practical Applications For PET \CT Imaging by Dr. H. Hawesa RAD 466-Lecture 7.
Response of the sensors to different doses from tests in Israel Radiotherapy is used as a treatment in around 50% of cancer cases in the UK. Predominantly,
Biomedical applications of molecular imaging Tony Lahoutte UMons Nov-Dec 2011.
Gallium-68 – a candidate for use in clinical routine
DOE SUPPORT OF NUCLEAR MEDICINE RESEARCH Alan B. Packard, Ph.D. Vice President Radiopharmaceutical Sciences Council Society of Nuclear Medicine.
Metals in Medicine Consortium Sydney Cancer Centre.
RADIOPHARMACEUTICALS RADIOPHARMACEUTICALS FUNDAMENTALS 5/27/2016L2 1 Nuclear Pharmacy (PHT 433 ) Dr. Shahid Jamil SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Production of innovative radionuclides at ARRONAX and 211 At RIT F. Haddad GIP ARRONAX.
RADIOGRAPHY & IT’S MODALITIES SPRING INFORMATION WORKSHOP 2011.
1 By Maribel Aguilar. 2 What is Gallium Scan?  Type of nuclear medicine that uses radioactive tracers.  Radioactive tracers common use in gallium scan.
Progress of the SNM Clinical Trials Network Michael Graham, PhD, MD Clinical Trials Network Co-Chair SNM President 1.
Molecular Imaging & Positron Emission Tomography Nicholas Mulhern BME 281.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Nuclear Medicine Technique I 355 RAD L.Aya Ahmed Saeed.
BERAC April 2004 Radiopharmaceutical Sub- committee Report.
Introduction to nuclear medicine NMT 231 L.Aya Ahmed Saeed.
Introduction to NM Omima Adam NMT 231. What is nuclear medicine NM Is the branch of medicine that uses radiation and nuclear properties of radionuclide's.
Nuclear Medicine and PET rev this is now slide 1do not print it to pdf things to do (check off when complete): add revision date to cover page.
Wake Forest School of Medicine Translational Imaging Program Wake Forest Translational Science Institute (TSI) Akiva Mintz, MD, PhD, MHA.
Medical Physics & Cyclotrons Dr. Benito de Celis Alonso 1,2 1 FCFM-BUAP 2 Fundación para el Desarrollo Carlos Sigüenza
Nuclear medicine Essential idea Nuclear radiation, whilst dangerous owing to its ability to damage cells and cause mutations, can also be used to both.
Clinical Pharmaceutical Science
Wellcome Trust / Glaxo Smith Kline Translational Medicine Training Programme at Imperial College Dr Waljit Dhillo.
Introduction to Medical Imaging SPECT, Introduction to Medical Imaging SPECT, PET and Lesion Detection Guy Gilboa Course
Other management positions COMPETENCIES…
Positron Emission Tomography.
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
Molecular Imaging “101” The Role of Molecular Imaging in Cancer Briefing and Roundtable Washington, DC July 22, 2008 Martin G. Pomper, MD, PhD Russell.
Nuclear imaging for prostate cancer: What’s new?
"Approaches on the role of medical physicists in implementing the hybrid technologies in Nuclear Medicine". Papel de la FM en la implementación de los.
Organizational Structure of a Hospital
Learning Objectives By the end of this lesson you should…
Overview of Nuclear Technologies in Healthcare
Chapter 20 Lesson 20.2 magnetic resonance (MR) nuclear medicine
Sophie Lancelot, Luc Zimmer  Trends in Pharmacological Sciences 
Radioisotopes in Medicine
Positron Emission tomography
Presentation transcript:

ZW GMP Lab for production of PET tracers for clinical and translational research Luc Mortelmans, Guy Bormans, Koen Van Laere, Christophe Deroose, Alfons Verbruggen, Johan Nuyts

Tracks molecules in the body by external detection of gamma rays emitted during decay of short-lived positron emitting radionuclides positron emission tomography (PET) 1. Tracer injection + distribution throughout the body 2. External detection of gamma rays (PET camera) 3. Images representing tracer distribution are reconstructed

positron emission tomography (PET) Modelling of kinetic analysis of PET data provides parametric maps e.g. in vivo receptor occupancy Time-activity curves Plasma input curve Radiometabolite quantification Kinetic modelling Binding potential B max /K d

PET tracer production: layout Radiosynthesis incorporation of radionuclide in target molecule Purification and formulation Prepar. HPLC, sterile membrane filtration QC HPLC, GC, pH, sterility, pyrogens … Radionuclide production Cyclotron irradiation (fluorine-18, carbon-11) Generator (gallium-68)

PET tracer production: a race against time radionuclideHalf-life Fluorine min Gallium-6868 min Carbon-1120 min Cyclotron production radiosynthesis Purification & formulation QC Scanning & Sample processing

Why cGMP for PET tracers? Radiopharmaceutical for human use Intravenous administration For clinical trials: cGMP required

PET tracers for clinical research and cGMP: legal issues Belgian Royal Decree May 7th 2004 experiments on the human person CHAPTER XIII. – § 3 a …in the case of investigational medicinal products manufactured in Belgium, that each batch of medicinal products has been manufactured and checked in accordance with the principles and guidelines for good manufacturing practices EC Directives 2003/94/EC principles and guidelines of good manufacturing practice of medicinal products and investigational medicinal products for human use

PET tracers for clinical research and cGMP: legal issues Eudralex volume 4: Good manufacturing practices

Requested infrastructure infrastructure/equipment € 2,380,000 personnel € 238,000 maintenance contracts € 115,000 Total budget : €2,733,840 Radiolabelling modules € 1,071,000 hot cells € 850,000 quality control equipment € 457,000

Proposed financing Hercules foundation € 1,984,000 GE € 150,000 Siemens € 150,000 Johnson&Johnson € 200,000 Merck € 250,000 Total support from companies:€ 750,000 (27%)

Project fits in the strategy of K.U. Leuven - MoSAIC: “Molecular Small Animal Imaging Centre” - Radiopharmacy lab - Investment in building GMP lab - State of the art clinical pharmacology lab - Medical Image Research Center (MIRC) - Flanders “PET net” (network)

4 synthesis hotcells, 1 dispensing hotcell for FDG 6 synthesis hotcells, 1 dispensing hotcell for contract research New building level 01 FDG + Contract research

Nuclear Medicine Cyclotron MoSAIC Radiopharmacy Lab University Hospital Leuven Nuclear Medicine

“MIRACLE” (Molecular Imaging Research & Application Center Leuven) From bench to bedside

Antwerpen, VUB, KUL, RUG, UCL, ULG, ULB (UNIV – 7) Hasselt, Charlerloi, Kortrijk, Bodet, Antwerpen, Mont-Godinne (NIET-UNIV – 6) University Hospital Leuven Nuclear Medicine

Onco-imaging clinic & research Clinical research Medical Physics Radiopharmaceutical chemistry Cardiology A) Diagnosis - Lung tumours - GI tumours - Lymphoma - Sarcoma (GIST) - Breast tumours - Response evaluation early clinical trials B) Therapy Infection and inflammation Gene expression Reconstruction Kinetic modelling Image registration SPECT 99m Tc labeling 123 I labeling PET 18 F labeling 11 C labeling Data-analysis PET microPET SPECT microSPECT Bioluminiscense MRI microMRI Neurology & psychiatryRadiology Oncology

Nuclear neuro-imaging research Clinical research Medical Physics Radiopharmaceutical chemistry Cardiology Oncology Infection and inflammation Gene expression Reconstruction Kinetic modelling Image registration SPECT 99m Tc labeling 123 I labeling PET 18 F labeling 11 C labeling NeuroImaging Data-analysis PET microPET SPECT microSPECT Bioluminiscentie MRI microMRI Neurology & psychiatry - Movement disorders - Epilepsy - Dementia - Brain Tumours - Eating disorders - Anxiety and mood disorders Radiology

Experimental PET-CT Biograph 16-HiRez (contract research 2005)

MIRACLE : multidisciplinary platform Medical Physics Radiopharmaceutical chemistry Oncology Gene expression Reconstruction Kinetic modelling Image registration SPECT 99m Tc 123 I PET 18 F 11 C Data-analysis Neurology/psychiatry Stem cell research Cardiology Clinical Pharmacol ogy - Recruitment (esp. HV) - Screening - Drug admin - PK sampling -... Clinical Divisions - Patient recruitment Infection-inflammation Clinical nuclear medicine Radiology

drug review/ market Improved diagnosis/ therapy Position & Role of MoSAIC IMAGING SOLUTIONS Improved insights & novel hypotheses Novel diagnostic & therapeutic strategies imagingclinicalLife sciences core partners peripheral partners ‘basic’ research preclinical development clinical research MoSAIC Omics

PET MRI BLI CT US Dedicated small animal imaging equipment Clinical imaging equipment adapted to small animal scanning: SPECT MoSAIC multimodality imaging facility (2007)

Translational molecular imaging technique positron emission tomography (PET) microPET scannerclinical PET scanner Rat model of Parkinson’s disease imaging of dopamine transporter Patient with PDnormal

PET in drug development Identify Targets Find Leads Toxicology Clinical Trials Regulatory Approval Time (Years) $ 800 MM - $1.6BN 5317 Research Development Refine Leads LaboratoryClinic $$$ Slide courtesy of R Hargreaves, MSD Accept or Reject a Candidate or Hypothesis

PET in drug development PET provides -early clinical target validation -early clinical target occupancy data as a funtion of dose as a function of time p.i. development of PET probes for new targets in parallel to drug development by all major pharmaceutical companies (MSD, Novartis, J&J, SKB, Roche,…)

Therapeutic drugs and PET tracers Therapeutic drug PET tracer Bio-availability after oral dosing +++- Plasma half-life>6 h<30 min Toxicity+++- High affinity++++ High selectivity++++ Fast and efficient radiolabelling with 11 C or 18 F -+++

PET tracers for clinical research and cGMP: legal issues Eudralex volume 4: Good Manufacturing Practices Production cell class “C” air Aseptic activities Class “A“air

ISO-certification Nuclear Medicine (2005)

Center for Clinical Pharmacology Clinical Research Unit (1) Facilities hotel accommodation: –20 beds for overnight stay –sanitary facilities (3 showers) –2 recreational areas (internet access, TV, video, …) research laboratories (4 laboratories; 2 temperature controlled) laboratory for sample processing medication room secretary and offices meeting room / monitoring office archive

Center for Clinical Pharmacology Clinical Research Unit: study types

MoSAIC Molecular Small Animal Imaging Center Animal models of human disease D C A: µPET B: µCT C: µUS D:µSPECT E: µMRI F: BLI 380 m² Imaging 320 m² Support

3 synthesis hotcells 1 dispensing hotcell for FDG 10 synthesis hotcells for research 1 glovebox for dispensing Upgrade level 0: FDG (temporarily) + research 1 LAF- cabinet Sas